Value Added Corporate Services P Ltd

15/08/2026

80 years of unmatched growth, cultural richness, and a spirit that never backs down.

🇮🇳 Today, we celebrate a nation that thrives on progress and lives to help others. Happy Independence Day! ❤️✨

23/07/2026

President Trump announced a stepped, multi-year tariff schedule specifically targeting imported generic drugs. By providing a 2-year reprieve before imposing steep levies (100% in 2028, rising to 200% in 2029), the administration aims to force pharmaceutical companies to build manufacturing plants within the United States.
While the policy is framed as a penalty for companies that fail to "reshore" domestic production, industry experts and trade policy analysts question whether a 2-year runway is realistic or economically viable for the low-margin generic drug sector.

Key Highlights from the announcement :
1. The Tariff Timeline
Aug 2026 – Aug 2028: 0% tariff (a 2-year transition window).
Aug 2028: Tariff rises to 100%.
Aug 2029: Tariff doubles to 200%.
Scope: Applies only to generic drugs. Patented, branded, and innovative drug tariffs remain unchanged.

2. India and China Face High Exposure
India: Indian drugmakers supply nearly 50% of all generic medicines consumed in the U.S. (accounting for ~1/3 of India's total pharmaceutical exports). Analysts note this poses significant commercial and trade balance risks for New Delhi.
China: China dominates upstream manufacturing of Active Pharmaceutical Ingredients (APIs) (e.g., amoxicillin and heparin), meaning U.S. supply chains remain deeply tied to foreign inputs even if final assembly occurs elsewhere.

3. Feasibility & Market Dynamics
Is 2 Years Enough? Trade experts point out that building and validating U.S. pharma plants is exceptionally capital-intensive and time-consuming. Because raw inputs must still be imported, critics doubt even a 200% tariff will fundamentally alter the economics of generic manufacturing.

Risk of Product Discontinuations: Generic margins are already razor-thin. If domestic wholesalers refuse to absorb tariff-driven price increases, manufacturers may simply stop producing lower-profit essential drugs rather than build U.S. facilities, worsening potential drug shortages in USA

4. Broader Trade & Industry Context
Section 232 & MFN Deals: Earlier trade actions placed a 100% levy on patented pharma imports, though major drugmakers (e.g., Eli Lilly, Pfizer, Novo Nordisk) secured 3-year tariff exemptions by signing onto Most-Favored-Nation (MFN) drug pricing agreements.
Next Steps for Indian Drug Manufacturers:

Indian drugmakers and trade associations (like the Indian Pharmaceutical Alliance) are expected to pursue a multi-pronged approach: lobbying Washington for product-level exemptions, accelerating FDA approvals, pursuing U.S. contract manufacturing partnerships, and seeking alternative export markets.

President Trump announces a zero tariff on imported generic drugs through August 2026 before a phased escalation to 200% by 2029.

10/07/2026

🚀 Big News in Healthcare & IVF! 🚀

Chennai-based Iswarya Fertility Center has officially raised over ₹350 Crore (nearly $37 Million) in a milestone growth investment from healthcare private equity giant OrbiMed Asia.

This massive funding marks a significant moment as institutional investors increasingly focus on India's expanding fertility care market.

✨ Key Highlights of the Deal:

🏥 Fueling Expansion: The capital will be used to launch new fertility centers in existing and underserved markets across India.

🧬 Upgrading Infrastructure: Investments will pour into strengthening clinical infrastructure, upgrading digital capabilities, and expanding their embryology talent pipeline.

🌐 Global Ambitions: While the immediate focus remains on deepening their pan-India presence, the management has indicated plans to eventually expand into international markets.

📈 An Elite Footprint: Founded in 1986, Iswarya has grown to become Southern India’s largest fertility network, operating 85+ centers across 8 states and serving over 300,000 couples.

💡 Market Insight:
India’s shifting demographic trends—highlighted by the national total fertility rate dipping to 1.9 (below the 2.1 replacement rate)—combined with rising urban incomes, are driving unprecedented demand and investor interest in high-quality fertility treatment.

The capital will fund new centres, clinical infrastructure and digital capabilities as investor interest in India's fertility care sector gathers pace.

09/07/2026

🚨 Regulatory Alert:
DCC Proposes Strict Public Disclosure for Pharma Non-Compliance & Recalls

To bridge the enforcement gap between state and central drug regulators, the Drugs Consultative Committee (DCC) under the CDSCO has recommended a significant transparency mandate that will directly impact pharmaceutical operations and procurement workflows across India.

Key Highlights of the Proposed Directives:

🌐 Mandatory Public Disclosure: State drug authorities must publish all orders relating to license suspensions, cancellations, "stop production," or drug recalls directly on their official websites.

🗓️ Strict Monthly Deadlines: State regulators will be required to share details of these enforcement actions and complete Not of Standard Quality (NSQ) drug lists with the CDSCO before the 10th of every month.

📦 Packaging Supply Chain Oversight: The DCC has also proposed a sub-committee to explore a regulatory framework for registering all printed packaging material suppliers to curb the diversion of materials into counterfeit/spurious medicines.

Why This Matters for Stakeholders:

Procurement Integrity: The move aims to prevent non-compliant manufacturers from using photocopies of canceled product licenses to secure fresh supply and procurement orders.

Supply Chain Visibility: Real-time online data ensures that a drug recall or quality issue triggered in one state is instantly visible to distributors, pharmacies, and healthcare professionals nationwide.

Reputational Accountability: Public "naming and shaming" places an increased premium on robust Quality Assurance (QA) and strict adherence to manufacturing standards.

Enforcement alignment is shifting toward absolute transparency. Stakeholders across the supply chain must prepare for tighter scrutiny and faster public data sharing.

An expert panel has recommended that states publish all regulatory actions online and share monthly enforcement data with the central drug regulator to improve transparency

05/07/2026

Union Health Ministry sent a letter to States mandating a special fire safety audit drive for all public and private healthcare facilities, which must be completed and uploaded to the Ministry's Integrated Health Information Platform (IHIP) by July 31 2026

Mandatory Monthly Audits:
While over 4,000 facilities completed audits in May, the Center is now making these audits a strict, monthly routine for all hospitals, including private nursing homes.

Focus Areas:
The directive heavily emphasizes checking high-risk environments where patients are most vulnerable and less mobile, specifically ICUs, NICUs (Neonatal Intensive Care Units), nurseries, and other critical care units.

Trigger Event:
This national directive follows a recent fire incident in the operation theatre of the Chigateri District Hospital in Davangere, Karnataka (though luckily, no casualties occurred as surgeries hadn't started yet).

Guidelines Dissemination:
States are instructed to widely distribute the updated National Guidelines on Fire and Life Safety in Healthcare Facilities to make sure every hospital knows exactly what protocols to follow.

The decision from the central government aims to solve a historically reactive problem with two primary objectives:

Shift from Reactive to Proactive (Routine Integration): The primary goal is to shift fire safety from being a "one-time, check-the-box exercise" (usually done only after a tragedy happens) into a fundamental, routine part of everyday hospital management and patient safety protocols.

Protect Vulnerable Patients: By forcing a strict focus on ICUs and newborn nurseries, the objective is to dramatically lower the risk of mass casualties in areas where patients are completely dependent on staff and machinery to survive, ensuring that the infrastructure supporting them is structurally fire-safe.

The Union Ministry of Health and Family Welfare has directed all States and Union Territories to complete fire safety audits of all public and private healthcare facilities through a special drive and upload the findings on the Integrated Health Information Platform (IHIP) by July 31

04/06/2026

𝐖𝐞𝐛𝐢𝐧𝐚𝐫 𝐨𝐧 𝐂𝐑𝐀𝐂𝐊𝐈𝐍𝐆 𝐓𝐇𝐄 𝐀𝐈 𝐓𝐑𝐔𝐒𝐓 𝐂𝐎𝐃𝐄

FABA (Federation of Asian Biotech Associations) US Chapter is hosting a webinar on CRACKING THE AI TRUST CODE in association with Colaberry Inc.

𝗔𝗯𝗼𝘂𝘁 𝘁𝗵𝗲 𝗣𝗿𝗼𝗴𝗿𝗮𝗺: Discover why 95% of AI initiatives fail and what drives the 5% that succeed.

𝗦𝗽𝗲𝗮𝗸𝗲𝗿𝘀 :
1. Mr.Ram Dhan Yadav Katamaraja, Founder & CEO, Colaberry Inc
2. Dr.Ramkumar Kuncha, CEO, Arka Mark Ventures
3. Dr.Chaithanya Bandi, Professor, Kellog School of Management

𝐖𝐡𝐨 𝐬𝐡𝐨𝐮𝐥𝐝 𝐀𝐭𝐭𝐞𝐧𝐝: Researchers, Innovators, and emerging Professionals shaping the next era of intelligence.

𝗗𝗮𝘁𝗲 , 𝗧𝗶𝗺𝗲 : Saturday, June 06, 2026; 10 :30 - 11.30AM IST , 10:00 - 11:00PM PST

𝗪𝗲𝗯𝗶𝗻𝗮𝗿 𝗠𝗼𝗱𝗲 : Zoom meet

𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗟𝗶𝗻𝗸: https://bit.ly/4o4R6Rk

All are requested to register and join Dr. Ramdhan and expert panelists to explore trusted AI, Agentic systems, and enterprise transformation

13/05/2026

The Strategic Macro-Plan for FTA Utilization

The announcement by Union Commerce and Industry Minister Shri Piyush Goyal represents a fundamental pivot in India’s economic strategy. For decades, India’s trade narrative focused on the "negotiation" phase—getting partners to the table. This announcement signals that the focus has shifted entirely to ex*****on and utilization.

1. Bridging the "Utilization Gap"
India has historically faced low utilization rates for its FTAs compared to peers like Vietnam or Thailand. This plan seeks to change that through:

The 500-Delegation Blitz: Sending 500 industry-led delegations to FTA-partner countries within a 9-month window to establish immediate "boots on the ground" presence.

Targeting $2 Trillion: The overarching goal is to hit $2 trillion in combined exports of goods and services by 2030. This requires a double-digit growth rate that can only be achieved if businesses use the duty concessions currently available.

2. Infrastructure and E-commerce Integration
The plan moves beyond policy into physical logistics.

Global Warehousing: The government is planning to facilitate the setting up of warehouses in key markets (like the UAE and Australia). This allows Indian MSMEs to stock products locally abroad, enabling "next-day delivery" and making them competitive with local sellers.

Digital Empowerment: The launch of the Trade Connect e-Platform serves as a single window for exporters to check tariff benefits, rules of origin, and compliance requirements in real-time.

3. Human Capital: The 1,000 FTA Professionals
Recognizing that trade law is complex, the government is creating a new cadre of 1,000 FTA professionals. These experts are the "special forces" of trade, trained to help businesses navigate the technical barriers that often act as invisible walls to export growth.

The Institutional Role of 1,600 Industry Chambers

Minister Goyal’s narrative emphasizes that FTAs cannot be implemented from a desk in New Delhi; they must be implemented in the industrial clusters of Ludhiana, Tirupur, and Pune.

1. The Last-Mile Educational Link
Most of India’s 63 million MSMEs are unaware of how a Free Trade Agreement specifically benefits their product line.

Simplifying Complexity: Chambers of commerce act as translators. They take 500-page legal documents and distill them into "Sectoral Guides" for their members.

Demystifying Rules of Origin (RoO): To get duty-free access, a product must meet "value-addition" criteria. The 1,600 chambers are being empowered to teach businesses how to track and document their supply chains to prove their goods are truly "Made in India."

2. Decentralized Trade Centers
By engaging 1,600 chambers, the government is effectively decentralizing the Ministry of Commerce.

Technical Hubs: Each chamber will serve as a lighthouse for local exporters. With the stationing of trained FTA professionals within these chambers, a small-scale manufacturer can simply visit their local chamber.

Certification Authority: Chambers play a vital role in issuing Certificates of Origin required to claim FTA benefits at foreign customs.

3. Market Intelligence and Feedback Loops
Chambers of Commerce provide the government with data

Identifying Non-Tariff Barriers: If Indian grapes are facing unfair testing standards in a partner country, or if Indian steel is being held up by arbitrary technical regulations, the chambers report this directly to the Ministry.

Matchmaking: During the 500 planned delegations, these chambers act as matchmakers, connecting their specific member base with verified buyers abroad, ensuring that trade visits result in actual purchase orders rather than just handshakes.

4. Competitive Spirit and "Atmanirbhar" Exports

The narrative highlights a cultural shift. The chambers are being urged to foster a competitive spirit.

The Minister's message is clear: Developed nations have the technology, but they have high costs. India has the talent and competitive manufacturing.

The chambers are the vehicles that will carry this Indian value proposition to the 160 countries they are connected with, ensuring that the benefits of globalization reach the smallest Indian entrepreneur.

India is launching ambitious plans to boost its use of free trade agreements. The commerce ministry will send 500 delegations abroad and train 1,000 people. This initiative aims to help Indian businesses increase exports and attract investments. The government is committed to supporting industry gro...

14/04/2026

Warmest greetings on the occasion of the Tamil New Year. May the coming year be filled with peace, stability, and significant milestones.

11/04/2026

𝐄𝐯𝐞𝐧𝐭 𝐔𝐩𝐝𝐚𝐭𝐞: 𝐈𝐧𝐭𝐞𝐫𝐝𝐢𝐬𝐜𝐢𝐩𝐥𝐢𝐧𝐚𝐫𝐲 𝐃𝐢𝐚𝐥𝐨𝐠𝐮𝐞 𝐨𝐧 𝐋𝐚𝐰 𝐚𝐧𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞

Today, All India Institute of Medical Sciences (AIIMS), Jodhpur and National Law University (NLU), Jodhpur have joined forces for a landmark stakeholders' consultation. This program aims to bridge the gap between legal regulation and medical science to foster a more robust healthcare ecosystem in India.

Objective

The primary goal of this consultation is to strengthen the interdisciplinary dialogue regarding the legal regulation of medical science and research. By bringing together regulators, clinicians, legal experts, and industry leaders, the session seeks to address complex regulatory hurdles and chart a collaborative way forward.

Key Topics Covered

Med-Tech Regulations: Deep dives into the 100% regulation of medical devices effective since April 2020, focusing on industry implementation and patient safety initiatives.

Medical Device Supply Chain: Essential insights into hospital licensing, procurement strategies, product recalls, and increasing patient awareness.

Medicine & Intellectual Property Rights (IPR): Expert discussions on patent protection for biomedical inventions and balancing commercial innovation with public health access.

Legal & Ethical Concerns in Healthcare: A dedicated panel discussion exploring the contemporary legal developments surrounding Euthanasia in India.

MedTech Jurisprudence: Examining the legal frameworks that govern medical technologies and their practical application.

Distinguished Speakers & Panelists

The event features insights from high-level dignitaries, including Dr. Rajeev Singh Raghuvanshi (Drugs Controller General of India), Hon'ble Mr. Justice Vinit Kumar Mathur (Rajasthan High Court), and leadership from both AIIMS and NLU Jodhpur.

Stay tuned for key takeaways as we continue to explore the intersection of law, ethics, and medical innovation!

AIIMS Jodhpur National Law University, Jodhpur